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ABSTRACT
Objective: The objective of the study was to assess the neuroprotective effect of azilsartan as a memory enhancer against scopolamine-induced 
amnesia in rats.
Methods: Albino Swiss male rats in equal numbers per group (n=6) were taken. Scopolamine hydrobromide was administered to induce amnesia 
within the rats. Control group rats were administered normal, negative control groups were administered with scopolamine to induce amnesia and 
nitrite during trials, positive control group rats were administered piracetam+ scopolamine and piracetam nitrite during trials, and test control group 
rats were administered azilsartan +sodium nitrite and azilsartan nitrite. Exteroceptive behavioral models just like the elevated plus-maze model, 
Morris water maze model, acquisition trials, and retrieval trial were wont to evaluate the neuroprotective effect of azilsartan.
Results: The scopolamine and azilsartan have a significantly decreasing effect on time spent within the target quadrant (TSTQ) but piracetam has an 
increasing effect. The effect of azilsartan on transfer latency time (TLT) was observed against scopolamine-induced amnesia in rats using the elevated 
plus-maze test. Piracetam was found to decrease the TLT and restore memory function at a better dose. Within the case of scopolamine treated rats, a 
big increase in TLT was noted. Azilsartan treated group also increased TLT within the elevated plus maze. It is noted that the scopolamine features a 
significantly increasing effect on escape latency time (ELT). Piracetam features a decreasing effect on ELT. A rise in ELT was seen because of azilsartan.
Conclusion: This study suggested that the azilsartan features a significant decreasing effect on TSTQ, azilsartan treated group also increased TLT and 
ELT.
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INTRODUCTION
Nootropics are drugs, supplements, and other substances which will 
improve cognitive function of the brain [1]. Nootropics also called smart 
drugs, memory enhancers, neuroenhancers, cognitive enhancers, and 
intelligence enhancers are drugs. Epidemiological studies of the Indian 
population reveal that dementia is essentially a hidden problem. Amnesia 
is often caused by a traumatic emotional event [2]. Today’s memory 
impairment may be a major problem because of dementia in elder 
people [3]. There are two different nootropics: Synthetic, a lab-created 
compound like piracetam, and notable natural and herbal nootropics, 
like ginkgo bilobal and American ginseng. Natural nootropics are proven 
in boosting the brain function while at an equivalent time making the 
brain healthier. Nootropics act as a vasodilator against the tiny arteries 
and veins within the brain [4]. The introduction of natural nootropics 
within the system will increase the blood circulation to the brain and at 
an equivalent time provide the important nutrient and increase energy 
and oxygen flow to the brain [5]. A number of the natural nootropics act 
as a positive allosteric modulator for acetylcholine (Ach) or glutamate 
receptors [6]. Commercialized natural nootropics within the market are 
reacting at different mechanisms, thus affecting different parameters. 
Natural nootropics alter the concentration of existing neurotransmitters. 
Natural nootropics are disclosed to stimulate the discharge of dopamine, 
uptake of choline, cholinergic transmission, function of α-amino-
3-hydroxy-5-methyl-4-isoxazole propionate receptor, turnover of 
phosphatidylinositol, and activity of phosphatase A2 [7]. Memory may be 
a process by which one encodes, stores, and retrieves information. Any 
disturbance within the process of acquisition/learning, retention, and 
recall, the three aspects end in the loss of cognitive ability with dementia 
in citizenry and amnesia in rodents, respectively [8]. Nitrite-induced 
severe vasodilatation and methemoglobinemia are responsible to supply 
cerebral hypoxia in experimental rodents. Scopolamine, the centrally 
acting anti-muscarinic drug with amnestic properties, has been used 
for many years in experimental animals to induce impairment in their 
performance of a spread of tasks requiring intact working and reference 
memory [9]. Scopolamine caused memory impairment, reduced 
cerebral blood flow, Ach level, elevated acetylcholinesterase activity, and 
malondialdehyde in rodents. Azilsartan may be a selective angiotensin 
II receptor antagonist utilized in the treatment of hypertension. The 
inhibition of the renin-angiotensin system (RAS) improves cognitive 
functions in hypertensive patients. RAS inhibition in hypertensive 
patients might be neuroprotective. Inhibition of the RAS could also be 
beneficial in attenuating cognitive deficits observed in aging, Alzheimer’s 
disease, paralysis agitans, vascular cognitive impairment, and post-
stroke cognitive impairment [10]. Scopolamine, a centrally acting anti-
muscarinic drug, impairs learning and memory both in rat and citizenry. 
Loss of the Ach, a neurotransmitter within the brain of patients with 
Alzheimer’s disease, appears to be a critical element to supply dementia. 
Ach was considered one among the neurochemical transmitters liable 
for memory retention. In humans, Ach, a key neurotransmitter for brain 
function, is synthesized locally within the cholinergic nerve endings [11].
METHODS
Drugs and chemicals
Piracetam (400 mg/kg) and scopolamine (0.400 mg/kg) were purchased 
from Jain Diagnostic Pvt. Ltd., New Delhi. Normal saline (10 mg/kg), 
azilsartan (10 mg/kg), and nitrite (75 mg/kg) were purchased from 
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Central Drug House (Pvt.) Laboratory (CDH), Daryaganj, New Delhi. All 
others unlabeled and reagents were analytical grade.
Animal care and selection
The normal weight of Swiss albino male rats was 150–200 g. The 
hotness of the experimental animal room was maintained to be 22°C 
(±3°C). Lighting was artificial, the sequence being 12 h’ light, 12 h’ 
dark. For feeding, conventional laboratory diets are used with water 
supplied. Healthy male rats are assigned to the control, standard, and 
action group. The protocol was accepted by the Institutional Animal 
Ethics panel (IAEC), approval no. MIET/IAEC/2019/JAN/16.
Behavioral animal models
Exteroceptive behavioral models
Morris water maze model: Morris water maze model is used to judge 
learning and memory. It consists of a circular cistern (diameter 150 m 
and height 45 cm), stuffed with water maintained at 25°C. The water 
is formed opaque with a white-colored dye. The tank is split into four 
equal quadrants with the assistance of two threads, fixed at the proper 
angle to every other on the rim of the pool. A platform (10 cm) of 29 cm 
height is found within the center of one of those four quadrants. The 
position of the platform and clues is kept consistent throughout the 
training session [12].
Acquisition trials: Within the acquisition trial after 1 h from drug 
administration, each rat was allowed in water for 120 s to search out 
the hidden platform from each quadrant and escape latency time (ELT), 
the time taken by rats to search out the hidden platform was noted. 
When a rat was unable to search out a hidden platform within 120 s, 
then the ELT was noted to be 120 s. After each trial, rats were stayed at 
the hidden platform for approx. 30 s to memorize the situation (Table 1 
and Fig. 1) [9].
Retrieval trial
On the day of the retrieval trial, the hidden platform was removed and 
after 1 h of dosing each rat was allowed into the pool for 120 s from each 
quadrant and therefore the time spent within the Q4 target quadrant 
(time spent in target quadrant [TSTQ]) within 120 s was noted (Fig. 2).
Elevated plus-maze model
The elevated plus maze served because the exteroceptive (where 
stimulus existed outside the body) behavioral model to judge 
knowledge and memory in rats 13. The apparatus consists of two 
open weapons (15 cm×10 cm) and two enclosed arms (15 cm×10 
cm×14 cm). The arms extended from a middle platform (10 cm×10 
cm), and therefore, the maze is elevated to a height of 50 cm from the 
ground. On the primary day, each rat is going to be placed at the top 
of an open arm, facing far from the central platform. Transfer latency 
time (TLT) is going to be the time taken by the rat to maneuver into 
anybody of the covered arms with all its four legs. TLT is recorded on 
the primary day. If the rats do not enter into one among the covered 
arms within 90 s, they are going to be gently pushed into one among 
the two covered arms, and therefore, the TLT are going to be assigned 
as 90 s. The rats are going to be allowed to explore the maze for 
10 s then return to its home cage. Memory retention is going to be 
calculated 24 h of acquisition trial on the 2nd day as inflation ratio 
using the subsequent formula described by inflation ratio = L1- L0/
L0 where L0 is TLT after 24 h and L1 is that the initial TLT in second 
(Fig. 3) [13].
Introspective behavioral models
Induction of scopolamine-induced amnesia within the rat: Scopolamine 
hydrobromide (0.3 mg/kg, i.p.) was administered to induce amnesia. 
Scopolamine may be a muscarinic receptor antagonist with amnestic 
properties that are used for many years in experimental rats to induce 
impairment in their performance of a spread of tasks requiring intact 
working and reference memory. Scopolamine has also been second 
hand clinically as an adjunct to the surgical or obstetric procedure to 
induce sedation and post-procedural amnesia [14]. This reversible 
amnestic effect was induced by centrally acting muscarinic cholinergic 
antagonists. Indeed, blockade of central muscarinic receptors could 
induce a pattern of cognitive impairment. Scopolamine actions are 
limited to the blockade of brain function mediated through cholinergic 
(muscarinic) receptors. Scopolamine, however, is comparatively 
non-selective pharmacologically concerning receptor subtypes, and 
therefore, the drug does not discriminate considerably concerning 
receptor subtypes, and therefore, the drug does not discriminate 
considerably concerning brain region although the scopolamine 
reversal model is in wide use in preclinical stages of drug development, 
in clinical trials [15].
Experimental protocol
Rats used for time spent within the target quadrant (TSTQ) and 
TLT were allocated into nine experimental groups and every group 
contained six rats.
•	 Group 1: Control group: Rats were administered normal saline (0.9% 
common salt solution; 10 ml/kg, i.p.) hour before the acquisition 
trial for 4 consecutive days and hour before the retrieval trial on 
day 5
Table 1: Experimental groups for escape latency time
Groups (n=6) Treatments Dose
Control Normal saline 10 ml/kg2
Negative control Scopolamine 0.4 mg/kg3
Standard per se Piracetam+Scopolamine 400 mg/kg+0.4 mg/kg
Test drug Azilsartan+Scopolamine Low dose 10 mg
Test drug Azilsartan+Scopolamine High dose 20 mg
Fig 1: (a and b) Effect of azilsartan on ELT during acquisition trials 
trial. Group I – Control (normal saline), Group II – negative control 
(sodium nitrite), Group III – standard per se (piracetam+sodium 
nitrite), Group IV – test drug (test drug+sodium nitrite), Group 
V – test drug (test drug+sodium nitrite) (significant increase 
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•	 Group 2: Negative control group: Rats were administered 
scopolamine (0.4 mg/kg; i.p.) during acquisition trials conducted 
from day 1 to day 4 then subjected to the Morris water maze test. 
On day 5, rats were administered normal saline (0.9% common salt 
solution; 10 ml/kg, i.p.), then subjected to a retrieval trial after hour
•	 Group 3: Negative control group: Rats were administered nitrite 
(75 mg/kg i.p.) during acquisition trials conducted from day 1 to 
day 4 then subjected to the Morris water maze test
•	 Group 4: Positive control group (piracetam-treated group): Rats 
were administered piracetam (200 mg/kg, i.p.) + scopolamine 
(0.4 mg/kg i.p.) during acquisition trials conducted from day 1 to 
day 4 so subjected to the Morris water maze test
•	 Group 5: Positive control group (piracetam-treated group): Rats were 
administered piracetam (400 mg/kg) +sodium nitrite (75 mg/kg i.p.) 
during acquisition trials conducted from day 1 to day 4 then subjected 
to the Morris water maze test
•	 Group 6: Test control group: Rats were administered azilsartan 
(10 mg/kg; p.o) hour before and scopolamine (0.4 mg/kg, i.p.) half-
hour before during acquisition trials conducted from day 1 to day 4 
then subjected to Morris water maze test
•	 Group 7: Test control group: Rats were administered azilsartan 
(20 mg/kg; p.o) hour before and scopolamine (0.4 mg/kg, i.p.) half-
hour before during acquisition trials conducted from day 1 to day 4 
then subjected to Morris water maze test
•	 Group 8: Test control group: Azilsartan (10 mg/kg; i.p.) hour before 
and nitrite (75 mg/kg, p.o) half-hour before during acquisition trials 
conducted from day 1 to day 4 then subjected to Morris water maze test
•	 Group 9: Positive control group: Azilsartan (20 mg/kg; i.p.) hour 
before and nitrite (75 mg/kg, p.o) half-hour before during acquisition 
trials conducted from day 1 to day 4 then subjected to Morris water 
maze test. Rats used for ELT were allocated into five experimental 
groups and every group contained six rats [16].
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 5.0 (version 
5.03). All the experimental data were expressed as mean±SEM. Result 
comparisons were carried out using a one-way analysis of variance 
followed by Tukey’s multiple comparison test to compare means 
among the groups. For the statistical tests, p<0.05 was considered to be 
statistically significant.
RESULTS
Pharmacological screening using Morris water maze model
Effect of Azilsartan on scopolamine and sodium nitrite-induced changes 
in ELT during acquisition trials
Azilsartan was investigated for its effect on scopolamine-induced 
amnesia and nitrite using the Morris water maze test. Azilsartan was 
administered at 10 mg/kg, p. o. and 20 mg/kg, p. o. doses in rats. The 
ELT of azilsartan conducted on 4 consecutive days is shown. It is noted 
that the scopolamine features a significantly increasing effect on ELT. 
Piracetam features a decreasing effect on ELT. Increase in ELT was seen 
because of azilsartan.
Effect of azilsartan on scopolamine and sodium nitrite-induced changes 
in TSTQ during retrieval trial by Morris water maze method
Azilsartan was investigated for its effect on scopolamine-induced 
amnesia using the Morris water maze test. Azilsartan was administered 
at 10 mg/kg, p. o. and 20 mg/kg, p. o. doses in rats. The TSTQ of 
azilsartan is shown. Note that while the scopolamine and azilsartan 
features a significant decreasing effect on TSTQ but piracetam has 
an increasing effect. Scopolamine treated rat’s decreased TSTQ as 
compared to the target quadrant (Q4) of the control group. However, 
piracetam increased TSTQ and showed protection against scopolamine-
induced amnesia. Results were expressed as mean±S.E.M. with n=6 in 
each group. a=p≤0.05 versus TSTQ within the control group; b=p≤0.05 
versus TSTQ in scopolamine-treated group.
Fig. 3: Effect of azilsartan on transfer latency time by 
elevated plus maze method. Group I and II – control (normal 
saline), Group III – negative control (scopolamine), Group IV 
– negative control (sodium nitrite), Group V – standard 
per se (piracetam+scopolamine), Group VI – standard 
per se (piracetam+sodium nitrite), Group VII – test drug 
(test drug+scopolamine), Group VIII – test drug (test 
drug+scopolamine), Group IX – test drug (test drug+sodium 
nitrite), Group X – test drug (test drug+sodium nitrite) 
(significant increase [*p<0.0001] vs. control and significant 
decrease [@p<0.0001] vs. treated group)
Fig. 2: Effect of azilsartan on time spent within the target 
quadrant during retrieval trial. Group I–IV – Control 
(normal saline), Group V – negative control (scopolamine), 
Group VI – negative control (sodium nitrite), Group VII 
– standard per se (piracetam+scopolamine), Group VIII – 
standard per se (piracetam+sodium nitrite), Group IX – test 
drug (test drug+scopolamine), Group X – test drug (test 
drug+scopolamine), Group XI – test drug (test drug+sodium 
nitrite), Group XII – test drug (test drug+sodium nitrite) 
(significant increase [*p<0.0001] vs. control and significant 
decrease [@p<0.0001] vs. treated group)
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Effect of Azilsartan on scopolamine and sodium nitrite-induced changes 
in TLT of rats by Elevated plus-maze method
The effect of azilsartan on TLT at doses of 10 mg/kg, p.o. and 20 mg/kg, 
p.o. was observed against scopolamine-induced amnesia in rats using the 
elevated plus-maze test. Piracetam was found to decrease the TLT and 
restore memory function at a better dose. In the case of scopolamine-
treated rats, a major increase in TLT was noted. Azilsartan-treated group 
also increased TLT in elevated plus maze. Results were expressed as 
mean±S.E.M. with n=6 in each group. a=p≤0.05 versus TLT up to the mark 
group; b=p≤0.05 versus TLT in scopolamine-treated group.
DISCUSSION
Most of the smart drugs are related to psychotic drugs with the specific 
site of action on the receptor of brain and memory. Piracetam was used 
as standard medicine to reverse the memory deficit by scopolamine. 
Piracetam is a drug commonly used to treat amnesia and is also used for 
the treatment of Alzheimer disease [7]. Scopolamine-induced amnesia 
test was used as an interoceptive model to induce amnesia in rats and 
the Morris water maze test and elevated plus maze test were used as an 
exteroceptive model. In Morris water maze test, acquisition trials animals 
learned to find a hidden platform to escape from water ELT and in the 
retrieval trial on the 5th day the highest TSTQ (Q4) shows the retrieval 
of memory [11]. Scopolamine produced impairments of memory in both 
acquisition trials and retrieval trials by increasing the ELT and decreasing 
the TSTQ. The azilsartan was investigated for its effect on scopolamine-
induced amnesia using the Morris water maze test. After the injection 
of scopolamine (0.4 mg/kg, i.p.), rats showed impairment of memory 
compared to that of the control group in which the little change in ELT 
was noted to find the hidden platform [17]. Azilsartan was administered 
at different doses (10 mg/kg, p.o. and 20 mg/kg, p.o), decrease in ELT 
to find the hidden platform, and the time spent by the rats in the target 
quadrant was taken as the index of retrieval. Further estimation of TLT 
was done with the help of elevated plus maze [18]. TLT was measured 
on 4 and 5 days of study. Azilsartan-treated group also increased TLT in 
elevated plus maze. Note that while the scopolamine and azilsartan have 
a significant decreasing effect on TSTQ but piracetam has an increasing 
effect. Azilsartan was found to increase the TLT [19].
CONCLUSION
Memory enhancing effect of azilsartan was investigated against 
scopolamine-induced amnesia in rats applying MWM test and EPM 
tests. Azilsartan was given at the dose of 10 mg/kg, p.o. and 20 mg/kg, 
p.o. Scopolamine was given at the dose of 0.4 mg/kg, i.p. before the test, 
drug to induce amnesia. An increase in ELT during acquisition trials 
and a decrease in TSTQ in retrieval trial show that azilsartan does not 
have memory enhancing property. Hence, both the screening models 
clarified that it does not have any kind of nootropic effect.
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